Sign In
Buy ALT
$2.92
+0.0500 (+1.74%)
At Close: Jun 04, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
03:46pm, Friday, 27'th Jun 2025
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to co
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts
02:39pm, Friday, 27'th Jun 2025
On Thursday, Altimmune, Inc. ALT released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
Altimmune: Deciphering The MASH Crash (Rating Upgrade)
04:30pm, Thursday, 26'th Jun 2025
Despite Altimmune, Inc.'s sharp selloff, I believe the market overreacted to pemvidutide's Phase IIb MASH data, which showed meaningful liver improvements and strong safety. The modest weight loss in
Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide
02:59pm, Thursday, 26'th Jun 2025
Altimmune, Inc.'s pemvidutide met the primary endpoint of MASH resolution in phase 2b IMPACT study which sets it on a continued development path going forward. The short 24-week trial duration likely
INVESTOR ALERT: Investigation of Altimmune, Inc. (ALT) Announced by Holzer & Holzer, LLC
01:14pm, Thursday, 26'th Jun 2025
ATLANTA, June 26, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) complied with federal securities laws. On
Altimmune shares plunge as MASH drug trial misses key fibrosis endpoint
12:11pm, Thursday, 26'th Jun 2025
Shares of Altimmune Inc (NASDAQ:ALT) tumbled 55% on Thursday after the company reported mixed results from a mid-stage trial of its experimental drug pemvidutide for metabolic dysfunction-associated s
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
08:16am, Thursday, 26'th Jun 2025
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.
Altimmune's weight-loss drug meets main goal in fatty liver disease trial
07:43am, Thursday, 26'th Jun 2025
Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease.
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
07:00am, Thursday, 26'th Jun 2025
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
07:12pm, Wednesday, 25'th Jun 2025
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
09:53am, Wednesday, 18'th Jun 2025
Eli Lilly (LLY -0.41%) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients w
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions
07:30am, Friday, 13'th Jun 2025
GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometa
ALT5 Sigma to Exhibit at iFX EXPO International June 17-19, 2025
12:00pm, Wednesday, 11'th Jun 2025
LAS VEGAS, NV / ACCESS Newswire / June 11, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1), a fintech specializing in turnkey, crypto-related solutions for institutions and merchants, is pleased
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
10:51am, Monday, 02'nd Jun 2025
I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in
Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity
10:25am, Thursday, 29'th May 2025
ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, alt
